Appeal No. 97-1999
Application 07/390,745
From Basic Science to Clinical Application,” FASEB Journal,
Vol. 1, No. 6, pp. 446-455 (1987); and Foster et al. (Foster),
“Taking Apart NMDA Receptors,” Nature, Vol. 329, pp. 395-396
(1987).
Claims 1-5 and 15 are representative of the subject
matter claimed and read:
1. A method of treating a
neuropsychopharmacological
disorder in a patient, wherein the neuropsychopharmaco-
logical disorder treated results from or is associated
with excessive activation of the N-methyl-D-aspartate
[(NMDA)] receptor complex, said method comprising:
administering to a patient in need of treatment
thereof a compound possessing partial agonist properties
for the strychnine insensitive glycine modulatory site of
the N-methyl-D-aspartate receptor complex in an amount
effective to alleviate the symptoms of the neuropsycho-
pharmacological disorder.
2. The method of claim 1), wherein the neuropsycho-
pharmacological disorder treated is selected from:
epilepsy, stroke, anxiety, Alzheimer’s disease,
Parkinson’s Disease, Guam ALS, dementia, and lathyrism.
3. The method of claim 1, wherein the neuropsycho-
pharmacological disorder is an epilepsy or anxiety
disorder.
4. The method of claim 1, wherein the disorder is
an epilepsy disorder.
5. The method of claim 1, wherein said compound has
the formula:
- 3 -
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Last modified: November 3, 2007